id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-351155-5bvo66yb	Kushner, Tatyana	Chronic Liver Disease and COVID‐19: Alcohol Use Disorder/Alcohol‐Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis	2020-05-21		.txt	text/plain	1806	101	43	6, 10 COviD-19 in PaTienTs wiTH nOnalCOHOliC FaTTY liver Disease/ nOnalCOHOliC sTeaTOHePaTiTis Given the association of COVID-19 severity with metabolic disease, the association with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) has • Minimize in-person contact with medical system • Interaction with the health care system should be via a "COVID-free" pathway 6,10 • Test for SARS-CoV-2 in the setting of acute decompensation or acute-on-chronic liver failure 10 An Official Learning Resource of AASLD Chronic Liver Disease and COVID-19 Kushner and Cafardi review also been investigated (Table 3 ). Finally, in another study of 214 patients in China, the presence of obesity in metabolic-associated fatty liver disease (MAFLD) was associated with a 6-fold increased risk for severe COVID-19. There are several key issues surrounding COVID-19 infection in patients with cirrhosis, including potentially increased risk for SARS-CoV-2 infection, higher risk for severe disease, and increased risk for hepatic decompensation (Fig. 1) .	./cache/cord-351155-5bvo66yb.txt	./txt/cord-351155-5bvo66yb.txt